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CHAPTER I 
 
INTRODUCTION 
 
Clostridium botulinum 
 Clostridium botulinum is a rod shaped, obligate anaerobe that is capable of 
forming spores and is commonly found in soil.  It is most notable for the production of 
the potent neurotoxin, botulinum neurotoxin or BoNT, the causative agent of botulism.  
The disease and etiology of botulism was first defined by van Ermengen in 1895 during 
an outbreak from salted raw ham in Ellezelles, Belgium. van Ermengen concluded that “it 
is highly probable that the poison in the ham was produced by anaerobic growth of 
specific microorganisms during the salting process” [1, 2]  He also concluded that the 
disease was from an intoxication rather than an infection [1, 2].  The organism was first 
defined as Bacillus botulinus but was later reclassified due to the restriction of the 
Bacillus genus to aerobes.     
 
Clostridium botulinum classification  
 The heterogeneous species C. botulinum is comprised of phylogenetically and 
physiologically diverse bacteria and is defined by the capacity of these bacteria to 
produce botulinum neurotoxin (BoNT).  Strains of C. botulinum are traditionally 
categorized into seven serological types (A through G) [3].  These seven serological types 
have been classified into four metabolic types and also contain C. butyricum and C. 
baratii,  which produce a toxin that cross-reacts with type E and F, respectively [4-6].  
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They have been divided into C. botulinum groups I-IV and are genetically different 
enough to merit four different species that are, in fact, more divergent than B. subtilis and 
Staphylococcus aureus [7] (Table 1).   
Proteolytic strains have a clostridial protease that results in post-translational 
proteolysis of the toxin [8].  Proteolytic strains (Group I and IV) include toxins A, B, F, 
and G.  These strains can produce a single active toxin (e.g. type A), can contain genes 
for two toxins but only produce a single toxin (e.g type A(B) which contains genes for 
both A and B serotypes but only produces A), or can contain genes for two toxins and 
produce one as a major and one as a minor toxin (e.g. type Ab, which would produce 
more type A serotype than type B) [9].  Non-proteolytic strains (Groups II and III) 
include serotypes B, E, and F and produce only a single active toxin.  In either of these 
strain classifications, the toxin gene can be located on the bacterial chromosome or on a 
large plasmid [10].  
 
Botulism 
Botulism is a rare, yet potentially deadly disease caused by exposure to BoNT. 
Exposure occurs through 3 major pathways: foodborne intoxication, wound infection, and 
intestinal colonization.  The clinical syndrome involves symmetrical cranial nerve palsies 
followed by descending symmetric flaccid paralysis of the voluntary muscles that can 
lead to respiratory failure [11, 12].  Botulism should be diagnosed and treated with anti-
toxin in less than 24 hours from the onset of symptoms.  The anti-toxin only neutralizes 
toxin that is not bound to or has not entered nerve endings.  Once inside the nerve cell  
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Table 1. Phenotypic differences between botulinum neurotoxin producing 
organisms.   
 
Characteristic Groups 
 I II III IV C. 
butyricum 
C. 
baratii 
Serotype A,B,F B,E,F C,D G E F 
Proteolysis + - - + - - 
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there is no treatment to prevent disease.  Severe intoxication may require intubation due 
to paralysis of the diaphragm and accessory breathing muscles.  Untreated botulism 
results in death due to the airway obstruction from pharyngeal muscle paralysis and a 
decrease in lung volume due to diaphragm and breathing muscle paralysis [11]. 
Foodborne botulism results from ingestion of food that has been contaminated 
with the toxin and does not require the bacteria to be present.  It is most commonly 
associated with two food sources.  One is in non-acidic canned foods, such as asparagus 
or mushrooms, where improper heating during the canning process has occurred.  Home-
canned foods are a major source of intoxication in the United States [13].  The other is 
native foods where the food is generally fermented and eaten uncooked [11].  This 
provides a suitable environment for spore germination.  Between 1990 and 2000 there 
were 263 botulism cases in the United States resulting from foodborne events [14].     
Wound botulism results from an infection at an open wound.  C. botulinum spores 
can get into an open wound and germinate in the anaerobic conditions of an abscess.  The 
conditions allow for in situ production of the toxin which can then access the blood 
stream in an intestine-independent manner.  While historically rare, the incidence of 
wound botulism in the United States has increased dramatically with the increase in 
needle-drug use [15]. Almost all of the needle-associated wound botulism comes from 
the use of “black tar heroin” [16].   
Intestinal botulism results from the germination of C. botulinum within the 
intestines of infants or adults.  Infants less than year of age are particularly susceptible 
due to an ‘immature’ normal intestinal flora that is less able to prevent C. botulinum 
germination and growth.  Infant botulism is the most common form of botulism and 
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results in between 80 to 100 cases a year in the United States [13].  Honey is a known 
source of C. botulinum spores and has been implicated in about 20% of all infant 
botulism cases [17, 18].  Adult intestinal toxemia results from a similar colonization of 
the intestine with C. botulinum and is typically a result of deformations within the bowel 
or extended antimicrobial therapy [19-21].  
Inhalation botulism is not a naturally occurring intoxication but can occur through 
the aerosol dissemination of BoNT [22, 23].  Inhalation intoxication poses a security risk 
due to the potential for weaponization of BoNT and the lack of a preventative vaccine.    
    
BoNT Function 
 BoNT belongs to a class of proteins known as AB toxins.  These toxins have an A 
fragment containing catalytic activity and a B fragment that delivers the A fragment into 
the cell cytosol.  Once the A fragment is released into the cytosol it can target its specific 
host protein (Figure 1).  A number of very potent toxins, including anthrax toxin, 
diphtheria toxin, and cholera toxin, belong to the AB toxin class. 
BoNT acts at the neuromuscular junction to block the release of acetylcholine 
vesicles into the synapse.  BoNT binds the neuron and is taken into the cell by receptor-
mediated endocytosis.  The pH drop in the endosome results in conformational changes 
that support membrane insertion of the B fragment and subsequent translocation of the A 
fragment into the cell cytosol.  Once the A fragment is within the cytosol it can cleave 
proteins involved in synaptic vesicle fusion.      
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Figure 1.  AB toxin pathways of entry. A) Example pathway using BoNT, an AB toxin.  B 
fragment (green) of BoNT binds to a surface receptor and is taken up using receptor mediated 
endocytosis.  The maturation and acidification of the endosome results in pore formation by the B 
fragment which allows for translocation of the A fragment (red) into the endosome. B) Example 
pathway using cholera toxin, an AB5 toxin.  B fragment (green) binds to a surface receptor and 
oligomerizes.  Receptor-mediated endocytosis traffics the toxin to the ER.  The A fragment (red) 
is unfolded and translocated into the cystol by ER machinery and refolds [24]. 
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Botulinum Neurotoxin Structure 
BoNT is expressed as a single 150 kDa polypeptide chain.  Proteolytic strains 
cleave, or ‘nick’, the polypeptide chain into a more toxic dichain form using a clostridial 
protease while non-proteolytic strains are believed to rely on a gut protease to generate 
the dichain form.  Generation of the dichain form leaves a 50 kDa light chain (LC) and a 
100 kDa heavy chain (HC) that remain tethered together by a disulfide bond (Figure 2A).  
The LC is composed of a single zinc endoprotease domain.  The HC is made up of two 
distinct domains, each about 50 kDa in size (Figure 2B).  The translocation domain is 
located at the N-terminus of the HC and is abbreviated HCT.  This domain forms a pore 
within the membrane of acidified endosomes and delivers the LC into the cytosol of the 
target host cell.  The receptor-binding domain is located at the C-terminus of the HC and 
is abbreviated HCR.  This domain is responsible for binding specific receptors at the 
neuromuscular junction and results in receptor-mediated endocytosis of the toxin.   
 The crystal structure for the BoNT holotoxin has been determined using BoNT/A 
(PDB 3BTA) [25, 26], BoNT/B (PDB 1EPW) [27], and BoNT/E (PDB 3FFZ) [28].  The 
crystal structures are notable in that they reveal an elongated translocation domain with a 
50 amino acid ‘belt’ that wraps around the LC.  The crystal structures of BoNT/A and /B 
have a linear arrangement of the three domains with the LC and HCR separated by the 
HCT.  BoNT/E has the HCR rotated 180o to lie adjacent to the LC, a configuration that 
has been observed in both the crystal structure and single particle reconstruction [28, 29].   
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Figure 2.  AB organization of BoNT Structure.  A) BoNT is produced as single 
polypeptide AB toxin that is proteolytically cleaved to separate the A fragment from the 
B fragment.  The two chains remained tethered by a disulfide bond.  The A fragment 
consisted of the 50 kDa LC.  The B fragment consists of the 50 kDa HCT and the 50 kDa 
HCR.  B) Crystal structure of BoNT/A showing the modular domain organization.   
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Receptor-Binding Domain (HCR) 
HCR is a two-lobed domain composed of two distinct subdomains (HCRN and 
HCRC) joined by an α-helix (Figure 3).  It is predominantly made up of β-strand 
secondary structure with distinct motifs for each subdomain.  The HCRN adopts a jelly-
roll motif from two seven stranded β−sheets, whereas the HCRC adopts a modified 
β−trefoil and β−barrel fold [27, 28, 30].  Despite being adjacent to the HCT in sequence, 
the HCR makes minimal structural contact with the HCT domain.   
The interaction of BoNT with the neuronal membrane is thought to require two 
receptors; a general receptor in the form of ganglioside and a high affinity protein 
receptor that confers serotype specificity [31, 32].  The ganglioside(s) that bind each 
serotype have been defined [33-38].  BoNT serotypes A, B, C, and F bind GT1b, GD1b, and 
GD1a [34-36, 38, 39].  BoNT/E binds GT1b and GD1a [33, 35] whereas BoNT/G recognizes 
all gangliosides with equal affinity [35].  BoNT/D lacks a ganglioside binding pocket but 
binds phosphatidylethanolamine (PE).  Blocking the ability of BoNT to bind ganglioside 
is protective [35, 40].  The first protein receptor identified was the vesicle fusion protein 
synaptotagmin (Syt) [41, 42], which is recognized by BoNT/B [43-45].  BoNT/G, like 
BoNT/B, binds both SytI and SytII isoforms [46].  Crystal structures of the complex 
between BoNT/B and an α-helical SytII peptide reveal the details of the binding site 
within HCRC [47-50] (Figure 3).   
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 Figure 3.  BoNT/B HCR bound to Syt II (2NM1).  Crystal structure of BoNT/B HCR 
(red) in complex with Syt II (blue).  GT1b (green) docked into the ganglioside binding site 
was superimposed from a structure of BoNT/A HCR in complex with GT1b (2VU9).  Both 
receptors bind the C-terminal lobe of the HCR (HCRC). 
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SV2 is an integral membrane glycoprotein with 12 putative transmembrane spanning 
regions that acts as the receptor for BoNT/A (SV2) [51], BoNT/E (glycosylated SV2A 
and SV2B) [52], BoNT/F (glycosylated SV2) [53], and more recently BoNT/D (SV2) 
[54].  Although no crystal structure has been determined of any SV2 isoform with any 
BoNT serotype, it is believed that a 130 amino acid extracellular loop is the site of 
binding for BoNT/A and BoNT/E [51, 52].  It has not yet been established where 
BoNT/F or BoNT/D interact, though it is known that they require both ganglioside and 
SV2 binding for neuronal uptake [53, 54].  BoNT/C has had no protein receptor identified 
and is believed to only bind ganglioside as a neuronal receptor [39, 55, 56]. 
  
Catalytic Domain (LC) 
  The catalytic domain (or LC) is a zinc metalloprotease that cleaves synaptic 
fusion SNARE (SNAP Receptor) proteins in order to inhibit vesicle/membrane fusion.  It 
is a globular structure composed of both α-helical and β-sheet secondary structure 
(Figure 2B).  The domain is surrounded by a 50 amino acid ‘belt’ from the translocation 
domain that partially occludes the active site [25, 27, 28].  The LC remains tethered to the 
HCT after nicking through a disulfide bond between residues C429 of the LC and C453 
of the HCT domain [25, 27] (Figure 2A).  The low pH within the mature endosomes is 
thought to cause unfolding of the LC.  Once inside the cytosol the LC refolds into a 
functional zinc endopeptidase specific for one of the three SNARE proteins.  Serotypes 
A, C and E cleave SNAP25 located at the plasma membrane [57-62].  Serotypes B, D, F, 
and G cleave VAMP/Synaptobrevin which is located on the synaptic vesicle [57, 63-67].   
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Figure 4.  BoNT/A LC complexed with SNAP-25.  Cocrystal structure of BoNT/A LC 
(wheat) bound to a SNAP-25 (blue).  SNAP-25 makes extensive contacts with the LC outside the 
active site.  The wrapping of SNAP-25 around the LC domain resembles the structure of the HCT 
belt (green) in the structure of the holotoxin (3BTA).  The active site zinc is depicted as the grey 
sphere.  
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Serotype C also cleaves Syntaxin, which is located at the plasma membrane [68, 69].  
The cleavage site is specific for each serotype.  Structural analysis of BoNT/A LC bound 
to a peptide of SNAP-25 shows extensive interaction between the two molecules [70, 71].  
The peptide wraps around the LC in a similar manner as the HCT belt (Figure 4).  The 
LC contains two exosites to accommodate the larger peptide and orient the scissile bond 
toward the zinc for cleavage [70]. 
 
Translocation Domain (HCT) 
HCT, the domain involved in pore formation and LC translocation, is a 
predominantly α-helical structure with a few unique features (Figure 5).  The N-terminal 
half of the domain (residues 453-688) is comprised predominantly of loops with a few 
short α−helices interspersed and includes the cysteine (C453) involved in the disulfide 
linkage with the LC and a 50 amino acid ‘belt’ that wraps around the LC [25, 27, 28].  
The belt occupies a similar position as the substrate and covers a large part of the LC 
surface utilized for substrate binding yet contains no scissile bond [70, 72].  The binding 
to substrate exosites may help the LC to refold into a catalytically functional state after 
translocation by providing scaffolding which would be similar to a competent binding 
state [72].  The C-terminal half (689-871) is comprised of a pair of coiled-coil helices that 
are 105Ǻ long.  The structure of HCT has no structural similarity with any other pore-
forming toxins (PFTs) (Figure 6) [73, 74].    
PFTs are loosely grouped into two categories based on elements of secondary 
structure.  α-PFTs are predicted to form channels using α-helices while β-PFTs tend to  
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 Figure 5. Structure of HCT.  A) Structure of HCT domain from the holotoxin structure 
3BTA.  HCT is predominantly α-helical with a 50 amino acid ‘belt’ that extends around 
the LC.  B) Surface representation of HCT (blue) with the LC (wheat) to highlight the 
‘belt’.  The top view shows the ‘belt’ completely surrounds the LC and makes extensive 
contacts with the LC.       
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Figure 6. Crystal structures of pore forming toxins.  A) Crystal structure of BoNT/A 
HCT,  B) Crystal structure of anthrax toxin protective antigen (PA) which make a β-pore 
(1ACC), and C) Crystal structure of diphtheria toxin translocation domain which inserts 
as an α-helix (1DDT).  Pore forming regions are colored dark blue for PA and diphtheria 
toxin.  There are is no structural homology between the 3 structures despite their ability 
to form protein-translocating pores.   
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be rich in β-sheet and utilize one or two β-hairpins from each monomer to form a β-
barrel structure that inserts into the membrane [75]. The rearrangement of secondary 
structure elements upon membrane insertion has been observed in a number of pore-
forming toxins [76, 77]. For example, the insertion sequence from perfringolysin O is α-
helical in the soluble protein but forms 2 transmembrane β-hairpins when inserted [76]. 
Knowing the secondary structure elements that span the membrane can help us  
understand how the resulting pore might function to transport ions, water, and/or protein.  
There has been extensive work establishing BoNT as a functional pore capable of 
translocating the LC.  The formation of ion conducting channels by BoNT has been 
demonstrated through the use of lipid bilayer experiments and more recently through the 
use of single channel clamp studies [78-83].  Translocation assays that track the 
movement of the LC across an artificial bilayer have shown that ion-conduction and LC 
translocation are connected [80, 84-87]. BoNT, and more importantly HCT, is capable of 
generating a protein-conducting channel that can translocate a functional LC in the 
absence of any host cellular proteins.  Since the functions of pore-formation and 
translocation are isolated to HCT, understanding the unique features of the HCT should 
provide insight into a key mechanistic step in BoNT intoxication. 
 
 
Research objectives 
 The goal of this research has been to understand the structures and structural 
changes associated with BoNT pore formation.  Herein, I will describe the expression, 
reconstitution, and biophysical analysis of BoNT/A LC-HCT with membranes.  In 
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collaboration with Dr. Audrey Fischer and Dr. Mauricio Montal, we have shown that LC-
HCT has the same channel activity as holotoxin and can translocate LC as a functional 
domain (Chapter II). I have developed a liposome reconstitution system that shows 
association of LC-HCT with liposomes in a pH dependent manner (Chapter II).  I have 
identified a region that is protected from pepsin when associated with liposomes and 
demonstrate this region moves to a more hydrophobic environment upon association with 
liposomes using single cysteine substitution and the cysteine-reactive environmentally-
sensitive nitrobenzoxadiazole (NBD) fluorophore (Chapter III).  Finally, in collaboration 
with Dr. Hassane Mchaourab and Dr. Hanane A. Koteiche, I performed an extensive 
analysis of LC-HCT single residue environments in both the soluble and liposome 
associated states using site-directed spin labeling and electron paramagnetic resonance 
spectroscopy.  The analysis reveals major conformational changes in the HCT structure 
upon association with liposomes and indicates the formation of an oligomeric membrane-
associated intermediate (Chapter IV). Together, these data support a model of how BoNT 
orients and associates with membranes of the endosome in response to low pH. 
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CHAPTER II 
 
RECONSTITUTION IN MEMBRANES 
 
Introduction 
  
The BoNT intoxication mechanism involves the formation of pH-dependent pores 
that serve as the conduit for translocation of the LC into the cytosol.  Pore formation has 
been localized to the HCT domain and the channels have been characterized as small and 
cation selective [29, 79].  The translocation of LC through these pores has been 
demonstrated using planar lipid bilayer and patch clamp methods and has provided 
significant insight into the biophysical process of pH- and potential- mediated channel 
activity [29, 85, 86].  The molecular structures that support pore formation and 
translocation have not been defined, however.  This chapter summarizes our efforts to 
generate functional reagents for the studies that will be presented in chapters 3 and 4. 
BoNT is considered a select agent, and recombinant protein expression is limited 
to one or two of the three functional domains. HCT is the domain associated with pore 
formation, but the expression of HCT alone or as HCT-HCR requires detergent 
solublization.  Detergents pose a potential problem when assessing the pH-dependent 
insertion of protein into liposomes.  The other 2-domain variant, LC-HCT, was likely to 
express as a soluble and correctly folded recombinant protein, however.  Further, the 
presence of the LC domain would provide an enzymatic activity allowing one to assess 
whether translocation across a barrier occurs [84, 86].  The goals in this study were to 
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generate an LC-HCT protein, assess whether LC-HCT behaves similarly to holotoxin in 
assays of pore formation and translocation, and mimic the endosomal conditions required 
for membrane insertion using liposomes. 
 
Methods 
 
Construction of BoNT/A LC-HCT.  DNA corresponding to the BoNT/A LC and HCT 
domains was obtained from two separate starting vectors: BoNT/A LC (unpublished 
results; a wild-type BoNT/A LC sequence) and HCT-SDmut [30]; a wild-type BoNT/A 
HCT amino acid sequence with silent mutations to disrupt an internal Shine Dalgarno 
site).  The LC was amplified with primers that introduced a 5′ NdeI site 
(GGAATTCCATATGCCATTTGTTAATAAAC) and 3′ Sac1 site 
(GGCGAGCTCGCTTATTGTATCCTTTATCTAATG) and ligated into a TOPO 
vector (Invitrogen, Carlsbad, CA).  An internal SacI site was then removed by 
QuikChange (Stratagene, La Jolla, CA) mutagenesis using the primer 
CTCTGGCACACGAACTGATCCACGCTGGTC and its reverse complement.  The 
BoNT/A HCT was amplified with primers that introduced a 5′ SacI site 
(GCCGAGCTCTGAACGATCTGTGTATCAAAGTTAATAATTGGG) and 3′ XhoI 
site (CCGCTCGAGGTTCTTAATATATTCAGTAAATGTAG) and ligated into a 
TOPO vector.  The LC and HCT domains were excised from the TOPO vectors using 
NdeI/SacI and SacI/XhoI, respectively and ligated into a pET24b vector that had been 
digested with NdeI/XhoI.  The use of the engineered SacI site results in the insertion of 
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an Arg between K447 (cat) and A448 (trans), a feature that was included in the design to 
improve the efficiency of trypsin activation. 
Recombinant LC-HCT Expression and Purification.  The plasmid pBL031 encoding the 
BoNT/A LC-HCT (residues 1-870 with a C-terminal deca-His-tag, [29]) was transformed 
into E. coli BL21 DE3 (RIL) cells.  A 100 ml overnight culture was added to 1 L of 
Terrific Broth and grown for 75 minutes.  The culture was diluted two-fold into fresh 
media and induced using 1 mM isopropyl-β-D-thiogalactopyranoside.  Cells were 
harvested after overnight growth at 18°C and stored at -80oC.   Pellets were resuspended 
in 20 mM Tris-HCl pH 8.0, 150 mM NaCl and lysed using a French Press.  Supernatants 
were clarified by centrifugation at 20,000 x g for 25 minutes and filtered with a 0.45 μm 
syringe disc filter.  Supernatant was added to a 10 ml bed volume of Talon Metal Affinity 
Resin (Clontech) charged with Co2+.  The column was washed with 50 ml 20 mM Tris-
HCl pH 8.0, 150 mM NaCl followed by 50 ml 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 
10 mM Imidazole.  The LC-HCT protein was eluted in 20 ml 20 mM Tris-HCl pH 8.0, 
150 mM NaCl, 200 mM Imidazole, concentrated to 5 ml, and purified on a Fast Flow Q 
Sepharose column (G.E.  Healthcare) using an elution buffer gradient of 20 mM Tris-HCl 
pH 8.0 from 0 to 500 mM NaCl.  The peak from the Q Sepharose column was 
concentrated to 1 ml and run over a Superdex S200 preparative grade size exclusion 
column (G.E. Healthcare) in 20 mM Tris-HCl 8.0, 150 mM NaCl for final purification.  
The retention volume was consistent with the size of a monomer based on the retention 
profiles of gel filtration standards (Biorad). 
Construction of Single Cysteine Mutants.  We mutated the 3 free cysteines (C134, C166, 
C790) from the wild type LC-HCT construct (pBL031) to alanines to create a LC-HCT 
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3CA template (plasmid pBL242).  pBL242 was used as the background for all single 
cysteine mutations.  All mutations were made using a standard QuikChange Site-Directed 
mutagenesis protocol (Stratagene) and verified by sequencing.  Mutant proteins were 
expressed and purified as described above. 
Liposome Preparation.  A 2:1 mole ratio mixture of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine:1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
(POPC:POPG) (Avanti) in chloroform was dried under N2 and placed under vacuum for 
6 hours.  The dried lipid mixture was rehydrated overnight with constant stirring to a final 
lipid concentration of 13 mM in 10 mM HEPES, 100 mM KCl pH 7.5.  Rehydrated lipids 
were subjected to 3 rounds of freeze/thaw followed by extrusion through a 100 nm filter 
to obtain large unilamellar vesicles (LUVs). 
Association and Proteoliposome Isolation.  10 μg LC-HCT (10 mg/ml) was added to 100 
μl POPC/POPG in 1 ml 20 mM NaAcetate pH 4.4, 100 mM NaCl.  Proteoliposomes 
were isolated by spinning at 10,000 x g for 10 minutes at room temperature.  The 
supernatant was removed, and the proteoliposomes were resuspended in 1 ml 20 mM 
NaAcetate pH 4.4, 100 mM NaCl and then reisolated by centrifugation.  This step was 
repeated 4 times to wash away unbound or loosely bound protein.  The high pH 
association was performed as described above with two changes: the buffer was 20 mM 
Tris-HCl 8.0, 100 mM NaCl and liposomes were isolated at 100,000 x g for 45 minutes. 
Trypsin Nicking of LC-HCT.  Di-chain BoNT/A LC-HCT was generated by cleavage 
with trypsin: BoNT/A LC-HCT (0.5 mg/ml) was incubated with 1 µg/ml trypsin 
overnight at 22±2°C.  Thereafter, trypsin was inactivated with 0.25 mg/ml trypsin 
soybean inhibitor for 15 min at 22±2°C. 
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Potassium release from POPC:POPG liposomes.  Liposomes were prepared as described 
above.  The liposomes were exchanged into 10 mM HEPES pH 7.5, 100 mM  NaCl using 
15 mL Sephadex G-50 size exclusion resin (Sigma).  One ml of exchanged liposomes 
were added to 5 ml 20mM NaAcetate pH 4.8, 100 mM NaCl for low pH, 20mM 
NaCitrate pH 6.0, 100 mM NaCl for intermediate pH, and 10mM HEPES pH 7.0 100 
mM NaCl for high pH.  Using a Orion 97-19 ionplus Potassium Electrode (Thermo), the 
solution was monitored until a baseline was established.  100 μl of 10 mg/ml LC-HCT 
was added and the voltage was monitored.  Once the voltage plateaued 5 μl of 20 mg/ml 
gramicidin in MeOH was added to see how much unreleased K+ was present.   
Protease activity of BoNT/A proteins.  Protease activity experiments were carried out by 
Audrey Fischer as previously described [29].  In brief, recombinant SNAP-25 was 
incubated with BoNT/A holotoxin or LC-HCT and cleavage products were visualized by 
SDS-PAGE. 
Cell culture and patch clamp recordings.  Cell culture and patch clamp recordings were 
carried out by Audrey Fischer as previously described [29]. In brief, patches from Neuro 
2A cells were excised in the inside-out configuration, and current recordings were 
obtained under voltage clamp conditions.   
Single-channel data analysis. Data from single-channel experiments were analyzed by 
Audrey Fischer as previously described [29]. In brief, analysis was performed on single 
bursts of each experimental record.  Only single bursts were analyzed due to the random 
duration of quiescent periods.  A single burst is defined as a set of openings and closings 
lasting ≥50 ms bounded by quiescent periods of ≥50 ms before and after. 
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Cell-based intoxication assay.  Cell-based intoxication assays were carried out by Audrey 
Fischer as previously described [29]. In brief, cleavage of endogenous SNAP-25 within 
Neuro 2A cells exposed to BoNT/A and truncation proteins were investigated. 
Western blot analysis. Western blots were performed by Audrey Fischer as previously 
described [29]. In brief, whole-cell extracts were probed for the presence of SNAP-25 
with anti-SNAP-25 mouse monoclonal IgG1 and visualized using an HRP-conjugated 
secondary antibody. 
Electron Microscopy.   To visualize the association of LC-HCT with liposomes at low 
pH,  proteoliposome pellets were analyzed by electron microscopy (EM) using 
conventional negative staining as described (152).  Proteoliposomes were diluted to final 
protein concentrations of 25 to 100 μg/ml and 2.5 μl aliquots were spotted onto glow-
discharged copper-mesh grids (EMS) for approximately 1 min.  The grids were washed in 
5 drops of 20 mM NaAcetate, pH 4.4, 100 mM NaCl followed by one drop of 0.7% 
uranyl formate. Grids were then incubated on one drop of 0.7% uranyl formate for 1 min, 
blotted against filter paper and allowed to air dry. Images of liposomes alone or 
proteoliposomes were recorded using a FEI Morgagni run at 100 kV at a magnification of 
36,000X. 
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Results and Discussion 
 
Cloning, Expression and Purification of LC-HCT.   
LC-HCT was cloned by Dr. Borden Lacy into pET24b.  The normal hexa-His tag 
was modified to a deca-His tag for purification.  LC-HCT was expressed recombinantly 
in E. coli BL21 DE3 (RIL) cells because the codon usage of E. coli differs from C. 
botulinum.  LC-HCT was expressed as a soluble, 100 kDa recombinant protein and 
purified to >95% purity using metal-affinity, Q-sepharose, and size-exclusion 
chromatography.  The channel activity studies required activated LC-HCT which is the 
separation of the LC and HCT through proteolytic cleavage.  This leaves the two domains 
tethered together by the disulfide between C429 and C453.  Activation allows for the 
separation of the LC once the disulfide is reduced and can be mimicked through the use 
of trypsin.  
The generation of mutants for fluorescence and EPR studies required the mutation 
of 3 of the 5 native cysteines.  Native cysteines C134, C166, C790 were mutated to Ala 
because they lie within hydrophobic regions of soluble BoNT/A based on the crystal 
structure.  The other two cysteines, C429 and C453, formed a disulfide bond that was 
stable under all purification or modification conditions. 
  
BoNT/A LC-HCT forms a protein-conducting channel that translocates LC in a pH-
dependent manner.   
We compared holotoxin channel formation to that of LC-HCT in a single 
molecule electrophysiological assay (Figure 7).  Membrane patches were obtained from 
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Neuro2A cells and the pipet (cis-compartment) was filled with low pH buffer and toxin to 
mimic the low pH environment of the endosome [29]. BoNT/A holotoxin and LC-HCT 
(Figure 7C) produce channels that begin at a low conductance of ~14 pS but 
progressively increase to a stable value of 68 pS when recorded at -100 mV.  The 
ramping time and intermediate conductance states are believed to represent discrete 
transient steps that occur during the translocation of the LC.  The HC (Figure 7A) and 
HCT (Figure 7B) constructs show no low conductance states [80, 84, 86]. Previous 
studies using lipid bilayers have shown that detection of LC catalytic activity in the trans 
compartment corresponds with the maximum channel conductance [85, 86].    
For BoNT holotoxin, channel formation and LC translocation are dependent on 
ΔpH.  The BoNT must be in a low pH buffer (~ pH 5) to mimic the pH gradient across 
the endosomal membrane (Figure 8A, top panel).  If the cis-compartment containing 
BoNT holotoxin was held at pH 6 (Figure 8A, middle trace) or pH 7 (Figure 8A, bottom 
trace), no channel activity or translocation was detected [84]. We found something very 
different with LC-HCT.  LC-HCT translocation (Figure 8B, top trace) proceeded even 
under a modest ΔpH (6 in the cis- and 7 in the trans- compartments) (Figure 8B, middle 
trace). Remarkably, when the excised membrane patches were bathed in symmetric 
neutral pH solutions, the LC-HCT still formed channels with a 64 pS conductance, but 
low conductance intermediate states were not detected (Figure 8B, lower trace, and 8C, 
blue).  Based on CD analysis the LC remains folded at pH 7 and therefore cannot go 
through the ~15 Å diameter of the HCT channel [80, 84].  This allows the HCT channel 
activity to form channels that are unperturbed by LC translocation.   
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Figure 7. BoNT/A HC, HCT, and LC-HCT channel activity measured on excised 
patches of Neuro 2A cells. Representative single-channel currents at the indicated 
voltages; consecutive voltage pulses applied to the same patch for each experimental 
condition. Channel opening is indicated by a downward deflection; C and O denote the 
closed and open states. γ values for HC (A) = 65.3±0.4 pS, HCT (B) = 64.4±0.4 pS, and 
LC-HCT (C) = 69.2±0.9 pS. The sections of the recordings obtained at −110 mV 
delimited by the black bars are shown in the bottom traces at a 10-fold higher time 
resolution; the prototypical square events which are characteristic of unitary channel 
currents are clearly discerned. An interpretation of the results is schematically illustrated 
at the bottom of each panel: The membrane is depicted as a grey bar with magenta 
boundaries; LC–purple, HCT–orange, HCR–red, and the cysteine involved in the LC-
HCT disulfide crosslink–green sphere; the SV2 protein-receptor is illustrated in yellow 
and the GT1b co-receptor in black (ceramide moiety inserted in the bilayer) and lime (the 
polar head group); the pH and redox conditions on the cis and trans compartments are 
indicated. These conventions also hold for Figure 8. 
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Figure 8.  BoNT/A holotoxin and LC-HCT channel activity in excised patches of 
Neuro 2A cells over a range of pH values in the cis compartment. A and B) Top 
panels illustrate channel activity monitored with ΔpH 5 cis/7 trans, middle panels show 
ΔpH 6 cis/7 trans, and bottom panels show ΔpH, 7 cis/7 trans. (A) BoNT/A holotoxin 
channel activity elicited under pH 5/pH 7 begins 10 min after GΩ seal formation, t = 0 s, 
and transitions from a low conductance intermediate state to the unoccluded state after 
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completion of LC translocation. The vertical lines indicate gaps to accommodate the full 
recording in the limited space. A schematic representation is depicted under the records 
for panels A and B. BoNT/A holotoxin does not form channels under pH 6/pH 7 or pH 
7/pH 7. B, BoNT/A LC-HCT channel activity begins 10 min, 12 min, and 45 min after 
GΩ seal formation for pH 5/pH 7, pH 6/pH 7, pH 7/pH 7, respectively. (C) Average time 
course of conductance change for BoNT/A holotoxin pH 5/pH 7 (black circle) (t1/2 = 
105±20 s), HC pH 5/pH 7(gray square), LC-HCT pH 5/pH 7 (red circle) (t1/2 = 130±10 s), 
LC-HCT pH 6/pH 7 (magenta circle) (t1/2 = 190±10 s), and LC-HCT pH 7/pH 7 (blue 
circle), (3≤n≤6 per data point; average N per data point = 829 events). No channel 
activity was detected for BoNT/A holotoxin under pH 6/pH 7 (black triangle) (n = 8) and 
pH 7/pH 7 (black square) (n = 8) conditions. (D) Analysis of unoccluded channel activity 
for BoNT/A holotoxin pH 5/pH 7 (black circle) (V½ = −67.2±2.9 mV), BoNT/A LC-HCT 
for pH 5/pH 7 (red circle) (V½ = −59.0±9.1 mV), BoNT/A LC-HCT for pH 6/pH 7 
(magenta circle) (V½ = −28.1±4.5 mV), BoNT/A LC-HCT for pH 7/pH 7 (blue circle) 
(V½ = −64.1±2.9 mV). 
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BoNT/A LC-HCT cleaves its substrate, SNAP-25, in intact Neuro 2A cells. 
The activity of LC-HCT on excised membrane patches led us to wonder whether 
LC-HCT would be functional on cells.  BoNT/A holotoxin readily enters neuronal cells 
via receptor-mediated endocytosis where it then is in the proper environment for insertion 
and translocation.  We predicted that LC-HCT would be ineffective since it lacks the 
HCR to provide uptake. The ability of LC-HCT to insert into the membrane and produce 
channels at neutral pH would suggest that insertion could occur at the plasma membrane, 
but we predicted that this insertion would not provide the low pH required for LC 
unfolding and translocation.  
To test this hypothesis, we utilized a cell-based assay that monitors the amount of 
intact versus cleaved endogenous SNAP-25 protein within Neuro-2A cells. In the absence 
of BoNT/A holotoxin or in the presence of isolated HCT, SNAP-25 remained intact 
(Figure 9A, lanes 1 and 8), whereas in the presence of BoNT/A holotoxin, a lower 
molecular weight proteolysis product of ~24 kDa was detected (Figure 9A, lane 2). 
Surprisingly, incubation of cells with LC-HCT resulted in proteolysis of SNAP-25 
(Figure 9A, lanes 3 and 4). The extent of proteolysis attained by LC-HCT was slightly 
lower than that produced by holotoxin but could be observed with a higher LC-HCT 
concentration. A single-chain BoNT/A LC-HCT unexposed to trypsin (Figure 9A, lane 5) 
or the LC-HCT that had the LC present in solution but released from HCT prior to the 
assay (Figure 9A, lane 6) did not cleave SNAP-25.  Cleavage of SNAP-25 by BoNT/A 
LC-HCT did not occur when cells were preincubated with 2 µM bafilomycin, a vesicular 
proton pump inhibitor that causes the endosome to remain at a neutral pH (Figure 9A, 
lane 7).  These results indicate that BoNT/A LC-HCT can enter neurons without the aid 
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Figure 9.  BoNT/A cleavage of endogenous SNAP-25 within Neuro 2A cells. (A) 
Representative western blot and (B) extent of SNAP-25 cleavage (average %) measured 
from western blots. (A) U and C denote uncleaved and cleaved SNAP-25. Blot shows 
SNAP-25 in the absence of BoNT/A - control (lane 1), SNAP-25 cleaved with 5 µg/well 
BoNT/A holotoxin (lane 2), with 5 µg/well (lane 3) and 30 µg/well (lane 4) LC-HCT. 
SNAP-25 was unaffected by incubation of cells with 5 µg/well BoNT/A LC-HCT single 
chain (lane 5) or reduced with TCEP prior to incubation with cells (lane 6), by incubation 
with 2 µM bafilomycin and 5 µg/well BoNT/A LC-HCT (lane 7) and by 5 µg/well 
BoNT/A HCT (lane 8). (3≤n≤per data point). 
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of the HCR, that LC entry does not arise from leaky cells or a non-specific mechanism, 
and that translocation requires the proteolytic activation step. The data were interpreted 
as follows: LC-HCT inserts into the plasma membrane at neutral pH and then must use a 
constitutive endocytic pathway to enter cells. Once inside the endosome, the low pH 
allows for the translocation of the LC, which can then release into the cytosol and cleave 
cellular SNAP-25.  Together, the results provide evidence that the HCR is not necessary 
for channel activity or LC translocation, and that the recombinant LC-HCT is a di-
modular BoNT endowed with the ability to deliver active LC protease into the cytosol of 
target cells. 
 
Isolation of BoNT/A LC-HCT proteoliposomes.  
Our next goal was to assess whether membrane insertion could be recapitulated in 
liposomes.  BoNT/A LC-HCT was purified as a soluble, recombinant protein at pH 8.0. 
The protein was incubated at pH 4.4 or pH 8.0 in the presence or absence of POPC/POPG 
liposomes. While pH had no visible effect on the solubility of either protein or liposomes, 
the low pH incubation of the mixture resulted in aggregation, similar to what has been 
reported in asolectin liposomes [88]. The aggregated liposomes were isolated by 
centrifugation and shown to contain BoNT/A LC-HCT by SDS-PAGE. The minimal loss 
of LC-HCT following multiple wash and reisolation steps shows that the interaction is 
irreversible at low pH. The lack of LC-HCT isolated with liposomes at high pH shows 
that low pH is required for the LC-HCT/liposome interaction (Figure 10B).  While this is 
in contradiction to the results obtained in the single-channel studies, we interpret this as a  
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Figure 10.  BoNT/A LC-HCT associates irreversibly with liposomes at low pH.  A) 
Structure of BoNT/A.  Coordinates are from model 3BTA with the HCR domain (not present in 
the sample) in mesh.  The LC domain is shown in wheat and the HCT is shown in light blue.  The 
disulfide and ‘belt’ that tether the LC and HCT structures together are highlighted to provide 
context of how the overall structure is arranged.  The hydrophobic 659-681 sequence is colored 
purple.  B) 10 μg LC-HCT (10 mg/ml) was added to 100 μl of POPC/POPG LUVs in 1 ml 20 
mM NaAcetate pH 4.4, 100 mM NaCl.   Proteoliposomes were isolated by spinning at 10,000 x g 
for 10 minutes at room temperature.  Half of the resuspended pellet (25 μl) was reserved for 
analysis in Lane 1 while the remaining half was washed four times (four cycles of resuspension 
and centrifugation) and then analyzed in Lane 7.   Supernatants from the initial proteoliposome 
isolation (concentrated to 50 μl) and the 4 subsequent washes (concentrated to 25 μl) were 
analyzed in lane 2 and lanes 3-6, respectively.   C) 10 μg LC-HCT (10 mg/ml) was added to 100 
μl of POPC/POPG LUVs in 1 ml 20 mM Tris-HCl 8.0, 100 mM NaCl.  Liposomes were isolated 
at 100,000 x g for 45 minutes.   Half of the resuspended pellet (25 μl) was reserved for analysis in 
Lane 1 and the other was resuspended in 1 ml 20 mM Tris-HCl 8.0, 100 mM NaCl and reisolated 
(Lane 4).   The supernatants from the initial proteoliposome isolation and subsequent wash were 
concentrated to 25 μl and analyzed in lane 2 and lane 3, respectively.   All proteins were 
separated by SDS-PAGE and visualized by Coomassie.  
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difference in now monitoring the bulk properties of the toxin.  If single molecules of LC-
HCT are associating with the liposomes at high pH, we will not observe them.  Another 
important difference to note is that the channel activity assays involve an applied 
membrane potential, which may play a role in membrane association and insertion in the 
lack of a low pH environment. The liposomes, on the other hand, do not have any active 
generator of membrane potential.   
 
Visualization of BoNT/A LC-HCT proteoliposomes.   
The LC-HCT proteoliposomes are isolated at a centrifugation speed where free 
liposomes and soluble protein will not pellet.  The only material we expect in the pellet 
are proteoliposomes, due to their aggregation, and possibly protein precipitate.  We 
wanted to ensure that the pellet was proteoliposome, so we used negative stain EM to 
visualize liposomes and proteoliposomes (Figure 11).  Images of free liposomes show 
single, round liposomes approximately 80-150 nm in diameter, consistent with the 
extrusion filter membrane size.  Proteoliposomes show a combination of large aggregates 
and some single liposomes.  The surfaces of the liposomes are covered in protein as seen 
by the staining whereas the background has minimal free LC-HCT particles.  Although 
the organization of LC-HCT on the surface of the proteoliposome is not clear, these 
images provide confidence that the 10k x g pellet consists of proteoliposome and not 
precipitated protein.       
 
 
 
 33
  
 
 
 
 
 
Figure 11.  EM images of LC-HCT proteoliposomes.  Negative stain images of 
liposomes alone (left) or proteoliposomes (right) were recorded using a FEI Morgagni 
run at 100 kV at a magnification of 36,000X.  A) Liposomes without LC-HCT added.  
Liposome size is approximately 100-150 nm as determined by the extrusion filter.  B) 
Proteoliposomes isolated from low pH liposome incubation with LC-HCT.  The protein 
stains white in color from the negative stain and can be seen covering the liposome 
surface although no details regarding structure can be determined. 
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Summary 
 
We expressed a two-domain variant of BoNT/A containing the LC and HCT.  We 
show that the LC-HCT is a soluble protein with a channel activity similar to that 
observed with BoNT holotoxin.  The one notable difference is that in the absence of the 
HCR, the LC-HCT does not have the same pH threshold requirement. We show that 
BoNT LC-HCT has the capacity to enter Neuro2A cells and translocate a functional LC.  
We have used this LC-HCT protein to develop a liposome reconstitution system that 
allows irreversible association of LC-HCT with liposomes under pH conditions observed 
in the endosome.  The association of LC-HCT with liposomes can be visualized using 
negative stain EM.     
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CHAPTER III 
 
IDENTIFICATION OF AN LC-HCT SEQUENCE THAT INTERACTS WITH 
LIPOSOMES 
 
Introduction 
  
  The pore formed by BoNT in membranes is solely attributed to the HCT [29] but 
the sequence that inserts into membranes has not been identified.  HCT is approximately 
50 kDa and testing at random to find regions that insert would be inefficient. Sequence 
algorithms have been used to predict an HCT sequence that has the potential of being a 
transmembrane spanning region [89] but the insertion of this region has not been 
confirmed in the context of the HCT.   
 A method that has been useful in identifying stable regions of insertion or sites of 
interaction is protease protection.  Liposomes should protect any regions of HCT that lie 
within the membrane from external protease.  This would not only confirm the validity of 
transmembrane predictions but produce fewer regions to test.  Similar studies have been 
effective with diphtheria toxin [90, 91] in determining regions that lie within the 
membrane during insertion.     
 In this chapter, we show that the association of LC-HCT with liposomes results in 
the pepsin protection of a 12 kDa and 5 kDa fragment.  The two major peptides identified 
from these fragments map to the C-terminal region of HCT (residues 805-837).  Using 
 36
the environment-sensitive fluorophore NBD, we have shown that the protected C-
terminal region shifts to a more non-polar environment upon liposome association.    
 
Methods 
 
Protection of LC-HCT by Liposome. 50 μl of 5 mg/ml pepsin in 10 mM HCl pH 2.2 was 
added to 10 μl of soluble LC-HCT (10 mg/ml) or LC-HCT proteoliposomes and 
incubated at 37oC for 12 minutes. Pepsin was quenched by the addition of loading dye 
(soluble LC-HCT) or 1 ml 20 mM NaAcetate pH 4.4, 100 mM NaCl (LC-HCT 
proteoliposomes). The proteoliposome sample was washed 3 times with 20 mM 
NaAcetate pH 4.4, 100 mM NaCl to remove pepsin.  
Peptide Identification by Mass Spectrometry. Isolated proteoliposomes after pepsin 
treatment were resuspended in 20 μl of SDS-PAGE loading buffer and 2 μl of 10% SDS. 
Resuspended proteoliposomes were run on a NuPAGE 10% Bis-Tris-HCl precast gel. 
Peptide bands were excised, trypsin digested, and extracted as described [92]. Digested 
protein samples were desalted using Michron CapTrap desalting cartridges (Michron 
Bioresources) using 2% acetonitrile/0.1% TFA and eluted in a volume of 50 μl using 
95% acetonitrile/0.1% TFA. The eluate was frozen on dry ice and lyophilized. Dried 
samples were then resuspended in 15 μl of 0.5% acetic acid in mass spectrometry-grade 
water. Samples were loaded onto 100 μm (internal diameter) fused silica columns packed 
with 12 cm of reverse phase resin (Synergi 4u Hydro RP80a, Phenomenex) and 
equilibrated using buffer A (0.1% TFA/5% acetonitrile). Peptides were eluted using a 
120-min linear gradient from 0-80% buffer B (0.1% formic acid/80% acetonitrile) at a 
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flow rate of 500 nl/min. Eluted ions were analyzed by nanoESI-LC MS/MS using a 
Thermo LTQ linear ion trap tandem mass spectrometer, as described [93]. All acquired 
MS/MS data were searched against the C. botulinum proteome using the SEQUEST 
algorithm. Search results were processed and analyzed using BIGCAT [94].  
Labeling Single Cysteine Mutants with IANBD. Purification for labeling of single 
cysteine mutants was the same as described in Chapter 2 except 1 mM Tris-(2-
carboxyethyl)phosphine was added at all steps and removed during the size exclusion 
purification. LC-HCT from the size-exclusion column was concentrated to 1 ml 
(approximately 1-5 μM) and labeled overnight at 4oC with a 10-fold molar excess of N-
((2-(iodoacetoxy)ethyl)- N-methyl)amino-7-nitrobenz-2-oxa- 1,3-diazole (IANBD) 
(Molecular Probes). Excess label was removed by passing the sample over a PD10 
desalting column (G.E. Healthcare). Labeled samples were concentrated to 30 μM and 
the labeling efficiency was determined using ε478 nm of 25000 M-1cm-1 for IANBD and 
the ε280 nm of 103280 M -1cm-1 for the LC-HCT protein. Samples not used immediately 
were flash frozen in liquid nitrogen and stored at -80oC.  
Fluorescence Spectroscopy. All fluorescence measurements were taken using a Horiba 
Jobin Yvon Fluoromax-3 (Horiba Scientific). The excitation wavelength for all 
measurements was 470 nm with a 4 nm slit width. Emission scans for both soluble and 
proteoliposome samples were taken from 500 nm to 600 nm in 1 nm intervals using a 4 
nm slit width. A buffer background emission scan was taken by adding 246 μl 20 mM 
NaActetate pH 4.4, 100 mM NaCl to a round quartz cuvette (model 1924 micro cell 
Horiba). 4 μl of 30 μM NBD-labeled LC-HCT was added and mixed by inversion 5 times 
and scanned again. The maximum fluorescence intensity at 530 nm was defined as Fsol. 
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Proteoliposome LC-HCT spectra were taken by adding 204 μl 20 mM NaAcetate pH 4.4, 
100 mM NaCl and 42 μl liposomes to a round quartz cuvette and taking an emission scan 
for the background. 4 μl of 30 μM NBD-labeled LC-HCT was added and mixed by 
inversion 5 times. The maximum fluorescence intensity at 530 nm for this sample was 
defined as Fmem. 
 
Results and Discussion 
 
Identification of protease protected fragments within BoNT/A LC-HCT 
proteoliposomes.   
Soluble LC-HCT and LC-HCT proteoliposomes were treated with 5 mg/ml pepsin 
in 10 mM HCl pH 2.2.  Pepsin completely proteolyzed soluble LC-HCT, but two low 
molecular weight bands were observed when LC-HCT was proteolyzed in the context of 
proteoliposomes (Figure 12A).  These bands appeared to be approximately 5 kDa and 12 
kDa in size.   Both bands were subjected to in-gel tryptic digest and mass spectrometry 
analysis.  Recovered tryptic peptides were separated by reversed-phase chromatography 
and analyzed by ESI mass spectrometry.  The majority of the peptides mapped to the C-
terminus of the HCT (805-820, 826-835) and localized within one region of the LC-HCT 
structure (Figure 12B).  Both bands contained the same array of peptides and it was 
observed that extended treatment with pepsin resulted in a decrease of the 12 kDa band 
and an increase in the 5 kDa band. The 5 kDa band might represent a minimized 
protected region and would correspond to ~ 30 amino acids.  30 amino acids are enough 
to span a membrane in an α-helical or extended conformation.   
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Figure 12.  Liposomes protect LC-HCT peptides from pepsin cleavage.  A) 20 μg of 
soluble LC-HCT without and with pepsin (lanes 1 and 2, respectively).  40 μg LC-HCT in 
proteoliposomes (lane 3) and 100 μg LC-HCT in proteoliposomes treated with pepsin (Lane 4).  8 
μg of pepsin (lane 5).  Arrows indicate LC-HCT peptides protected by the liposome.  B) An in-
gel tryptic digest of bands A and B followed by mass spectrometry suggests sequences that were 
protected from protease degradation in the context of the proteoliposome.  The two most 
abundant peptides (green) overlap to one region of the LC-HCT primary sequence: 805-821 and 
826-836.                
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Besides the peptides that mapped to the C-terminus of HCT, a few other peptides 
in the 5 kDa band are of interest.  Another pair of peptides that appear to be a continuous 
region between 700-730 lies at the N-terminus of the first long helix.  The 805-827 region 
lies antiparallel to the 700-730 region and interact with one another through hydrophobic 
residues.  A third peptide identified was from the catalytic domain (residues 319-330).  
This peptide, like the 805 and 700 peptides, lies on the same face of the LC-HCT soluble 
structure.  These peptides might suggest a face of the protein that can interact with 
membranes during insertion.     
 
Steady-state fluorescence of NBD-labeled LC-HCT in soluble vs proteoliposome 
forms. 
  Based on the protease protection results alone, it is not possible to determine the 
nature of the protection.  The protected region could be protected by the liposome as a 
result of insertion.  It is also possible that the region has repacked in a way that it is now 
more resistant to pepsin.  We used the environment-sensitive fluorescent dye NBD to 
determine how LC-HCT is protected.  The emission properties of the NBD fluorophore 
are sensitive to the polarity of the local environment: as the dye moves from an aqueous 
to a nonaqueous environment, the fluorescence intensity increases and the wavelength of 
maximum emission intensity decreases (blue shift).  Therefore, when introduced as a site-
specific label, NBD can be used to differentiate between residues that are in hydrophobic 
and hydrophilic environments. 
We generated a panel of NBD-labeled proteins with a special emphasis on two 
regions; 659-681 is the extended hydrophobic sequence identified by previous primary 
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sequence analyses [89] and the 805-820, 826-835 sequences were shown to be protease 
resistant in the context of proteoliposomes (Figure 13).  Each LC-HCT NBD mutant was 
examined spectroscopically for changes in NBD fluorescence intensity between soluble 
and liposome associated forms.  Typical spectra for a residue that shows an increase in 
NBD fluorescence upon association with liposomes (I830C-NBD) (Figure 14A) and a 
residue that shows no change in environment (I684C-NBD) (Figure 14B).  Changes in 
fluorescence intensity were analyzed by dividing the NBD fluorescence intensity of 
liposome associated LC-HCT (Fmem) by the NBD fluorescence intensity of the soluble 
LC-HCT (Fsol) at 530 nm (Figure 14C).  A large value means that the side-chain has 
shifted into a more hydrophobic environment upon association with the liposome.   
We see that residues in the 826-835 region show Fmem/Fsol values that are > 3 
and map to one tip of the HCT helical axis, specifically a loop connecting two α-helices.  
Mutation and testing of residues from a neighboring loop did not reveal a similar increase 
in NBD fluorescence (Figure 14C,D).  Fluorescence quenching experiments using NBD-
labeled proteins indicate that many of these residues (826-830, 832, 834-835) move into a 
hydrophobic environment upon conversion of LC-HCT from the soluble to liposome-
associated form (Figure 14C).  These data are consistent with a model in which these 
residues are protected at the membrane upon conversion to proteoliposome. The sequence 
of the loop is 826-RGTLIGQVDR-835, which is notable in that it contains charged and 
polar amino acids.  Arginines are of particular interest as these residues are often 
observed at protein membrane interfaces and have been implicated in voltage gating [95, 
96].   
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 Figure 13. Locations of NBD-attached single cysteine mutants used in fluorescence 
studies.  Residues from Fig. 14C mapped onto the structure of HCT.  Residues with Fmem/Fsol 
> 3 are colored blue and residues with Fmem/Fsol < 3 are colored red.  The peptide (805-836) 
identified by mass spectrometry is colored green and the predicted transmembrane sequence 
(659-681) is colored purple.  The locations of the HCR and the HCT ‘belt’ that surrounds the 
catalytic domain are marked. 
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 Figure 14.  Fluorescence intensity of NBD attached to cysteine-substituted LC-HCT 
in soluble and liposome-associated forms.   Emission scans of the soluble (red lines) and 
liposome-bound (black lines) forms of A) I830C-NBD and B) I684C-NBD at pH 4.4.   The large 
increase in intensity and blue shift to 530 nm when I830C-NBD binds to liposomes is consistent 
with movement of NBD into a non-polar environment.  C) Compilation of the NBD intensity 
changes (Fmem/Fsol) observed at 530 nm for specific LC-HCT residues when proteins in soluble 
(Fsol) and liposome-associated (Fmem) forms are compared.   Residues were selected throughout 
the HCT structure with an emphasis on the protease-protected region identified in Figure 2 (805-
836, green).  Residues from the neighboring loop (682-688, orange) are included to show this 
change is specific to the protease-protected region.  D) Close-up of the location of tested residues 
within the context of the LC-HCT structure.   Residues with an Fmem/Fsol > 3 are shown in blue 
and residues with Fmem/Fsol < 3 are shown in red.   
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Summary 
We describe 2 peptides that are protected from pepsin when in the presence of 
liposomes at low pH.  These peptides correspond to one continuous amino acid stretch, 
805-837, that is near the C-terminus of HCT.  We used an environmentally sensitive dye, 
NBD, to show that this region is shifting into a more hydrophobic environment upon 
proteoliposome formation.       
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CHAPTER IV 
 
DYNAMICS OF LC-HCT IN SOLUBLE AND LIPOSOME ASSOCIATED 
STATES 
 
Introduction 
 
 Low pH and the association of BoNT with membranes are believed to introduce 
only minimal amounts of secondary structure changes [97].  Single domain studies have 
attributed the majority of those structural changes to the LC [84].  The protein 
translocation model would suggest that the LC would have to partially unfold in order to 
be passed through a channel made by the HCT   We are interested in how the HCT 
appears to maintain its overall secondary structure with insertion into the membrane and 
what changes need to occur during this process. 
         Electron paramagnetic resonance (EPR) spectroscopy has proven to be an 
effective method in probing the structures of other pH-dependent pore-forming toxins 
[98].  In brief, the proteins are engineered to contain single cysteine residues at defined 
locations within the structure.  The proteins are labeled with a sulfhydryl specific 
nitroxide reagent and inserted into model membrane liposomes.  The paramagnetic 
resonance of the nitroxide side chain provides information on the mobility [99] and 
solvent accessibility of the side chain [100].  Studies of this nature have identified the α-
helical transmembrane elements in colicin E1 and diphtheria toxin [101, 102].  
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We used EPR to investigate conformational changes and membrane insertion within the 
HCT.  Lineshape analysis revealed that the predicted transmembrane sequence (659-681) 
undergoes a large conformational change.  The protease protected region (805-837) 
shows little conformational change upon liposome association.  EPR accessibility 
measurements, used to distinguish between polar and nonpolar environments, do not 
suggest a specific region is inserted into the membrane.   
    
Methods 
 
Labeling Single Cysteine Mutants with MTSSL.  Purification for labeling of single 
cysteine mutants was the same as described in Chapter 2 except 1 mM DTT was added 
during lysis and removed on the Talon Resin.  Immediately after elution from the Talon 
resin, 10-fold molar excess of S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl 
methanesulfonothioate (MTSSL) dissolved in dimethylformamide was added and 
incubated for 4 hours at room temperature. After incubation, 5-fold molar excess of 
MTSSL was added and incubated overnight at 4oC.  Unbound MTSSL was removed 
during further purification. 
Electron Paramagnetic Resonance of Single Cysteine Mutants.  EPR spectra were 
collected at 23°C on a Bruker EMX spectrometer (X-band) at an incident power of 10 
mW and 1.6 Gauss modulation amplitude.  Spectra of soluble LC-HCT single cysteine 
mutants were taken at 10 mg/ml protein concentration.  Proteoliposome samples were 
made by combining the pellets from 4 individual insertions, as described above. The 
combined pellets were washed 4 times with 20 mM NaAcetate pH 4.4, 100 mM NaCl 
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and resuspended in 40 μl of the same buffer.  Power saturation experiments were carried 
out on a Bruker ELEXSYS spectrometer equipped with a dielectric resonator (Bruker 
BioSpin).  Samples were loaded in gas-permeable methylpentene polymer TPX® 
capillaries, and the measurements were carried out under nitrogen gas alone, in the 
presence of 20% oxygen, or under nitrogen gas with 10 mM Nickel diaminediacetic acid 
(NiEDDA).  The data were analyzed to obtain the parameter P½ from a nonlinear least-
squares fit of the power saturation curves in the program Origin (OriginLab Inc.).  The 
EPR accessibility parameter Π was calculated as described [103] 
 
Results and Discussion 
 
Conformational changes in HCT structure revealed by EPR spectroscopy.   
The observation that protected residues are located at one tip of the BoNT/A HCT 
suggests the possibility that this region merely ‘dips’ into the membrane without 
undergoing a significant structural change.  To assess the extent of HCT structural change 
for residues throughout the structure, we collected EPR line-shape spectra for soluble and 
liposome associated LC-HCT using proteins labeled with MTSL at site-specific locations 
(Figures 15 and 16).  Qualitative assessments of relative changes in side chain mobility 
were based on 1) the overall breadth of the spectrum along the horizontal magnetic field 
axis and 2) the line width of the central resonance.  An increase in breadth is interpreted 
as a decrease in molecular ordering and/or motional frequency (24).  
The 805-837 region does not appear to undergo any structural changes upon 
liposome association (Figure 17A).  For example, L829C is a surface exposed residue in  
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 Figure 15. Locations of MTSL-attached single cysteine mutants used in lineshape 
analyses.  Qualitative assessments of relative changes in side chain mobility were based on 1) 
the overall breadth of the spectrum along the horizontal magnetic field axis and 2) the line width 
of the central resonance.  An increase or decrease in breadth is interpreted as a change in mobility 
and the sidechain is colored red.  Side chains without significant change in lineshape are colored 
in blue.  The peptide (805-836) identified by mass spectrometry is colored green and the 
predicted transmembrane sequence (659-681) is colored purple. The locations of the HCR and the 
HCT ‘belt’ that surrounds the catalytic domain are marked. 
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 Figure 16. Lineshapes of MTSL-attached single cysteine mutants.  To assess the extent 
of HCT structural change for residues throughout the structure, we collected EPR line-shape 
spectra for soluble and liposome associated LC-HCT using proteins labeled with MTSL at site-
specific locations.  Lineshape overlays of soluble (red) and proteoliposome pH 4.4 (blue) samples 
are shown.  Lineshapes in black are proteoliposome samples collected at pH 5.0.  All lineshapes 
were recorded with a 200G scan width unless otherwise specified. 
 53
the soluble form, as determined by both the structure and the EPR lineshape (Figure 
17E).  Upon conversion to the proteoliposome form, there is little to no change in the 
spectral lineshape for this residue or the nearby residues G827C and R835C.  This 
suggests that the 826-835 loop is moving into a more hydrophobic environment as 
detected by NBD fluorescence but the environment shift is independent of any detectable 
changes in motility.  Therefore it would be concluded that this loop is shifting into a new 
environment but without perturbations to its current structure.   
While many residues tested throughout HCT showed little lineshape change upon 
liposome association (Figure 15), the 659-681 hydrophobic region had a large number of 
residues showing lineshape changes (Figure 17A).  One residue, F666C, is buried at a 
turn within the 659-681 hydrophobic sequence and makes significant contact with the 
LC.  The EPR lineshape analysis confirms that F666C is immobile in the protein’s 
soluble form but is highly mobile after liposome incorporation at pH 4.4.  Interestingly, 
the lineshape at pH 5.0 showed a mixture of mobile and immobile states, representing 
spectral components of F666C in the soluble and liposomes-associated forms (Figure 
17B).  Other residues within this region that show large lineshape changes face the 
hydrophobic cleft that lies between the two long helices.  The lineshape change of these 
residues to more mobile states provides evidence that there are structural changes 
occurring in this region upon liposome association.    
 
Spin-Spin interaction. 
The measurement of EPR lineshapes to investigate the dynamics of BoNT 
association with membranes revealed a couple of residues that showed spin-spin 
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coupling, a phenomenon that arises when 2 spin labels are in close proximity.  Spin-spin 
coupling is detected by lineshape broadening and the presence of peaks at low- and high-
field positions not seen with a single spin label.  Two residues in the HCT showed spin-
spin coupling under low pH conditions. K805C showed spin-spin coupling when 
associated with liposomes at pH 4.4, but no spin-spin coupling was observed at pH 8.0 
(Figure 17D).  Residue I667C also showed spin-spin coupling but only under 
intermediate pH 5.0 conditions (Figure 17C), the same pH where neighboring residue 
F666C showed both mobile and immobile components.   
The presence of spin-spin coupling in these samples suggests that the inserted 
protein is in an oligomeric state.  This oligomerization would not be a result of receptor 
binding since both receptors and the HCR are missing.  The presence of spin-spin at pH 
5.0 for I667C, much like the presence of both mobile and immobile components in 
F666C, would lead us to believe that this pH might represent a transition state between 
the soluble and liposome-associated forms.  The spin-spin measured with K805C would 
reflect oligomerization at a final association state within our system.  We interpret these 
data to mean that during the process of liposome association, I667C residues from two 
monomers come into close proximity but as the pH decreases to 4.4 those residues 
separate and an oligomeric face around residue K805C is created.  
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Figure 17.  Lineshape measurements of MTSL attached to cysteine-substituted LC-
HCT in soluble and proteoliposome forms. A) Lineshape changes in the previously 
described hydrophobic sequence (659-681, purple) and protease-protected region (805-836, 
green). Side chains are colored according to large (red) or small (blue) changes when comparing 
lineshapes from soluble and proteoliposome samples.  Region 659-680 shows greater lineshape 
changes as compared to 805-836. (B-E) Representative lineshape overlays of soluble (red), 
proteoliposome pH 4.4 (blue), proteoliposome pH 5.0 (black) samples for mutants F666C (B), 
I667C (C), K805C (D) and L829C (E).  A 200G scan width was used for F666C, I667C, and 
L829C.  A 250G scan width was used for K805C.  All spectra were normalized to the same 
number of spins.    
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Accessibility Measurements of MTSL-labeled mutants.  
Accessibility measurements of MTSL-labeled LC-HCT mutants were conducted 
as a second method to differentiate between membrane inserted and solvent exposed 
residues in proteoliposomes.  This method takes advantage of the partitioning of two 
paramagnetic agents, O2 and NiEDDA.  NiEDDA will remain at the highest 
concentration in solution and O2 will partition into the membrane with the highest 
concentration found at the middle of the bilayer.  The measurement of collisions between 
MTSL and these paramagnetic agents can indicate if the side chain is solvent exposed or 
membrane oriented.  Analyzing the saturation behavior of the spin label can provide an 
accessibility parameter Π that is directly proportional to the collisions [98, 104] .  Soluble 
and membrane associated Π values result in three categories: 1)  High NiEDDA Π  
values suggest the residue is solvent exposed, 2) low NiEDDA Π values and low O2 Π 
values suggest the residue is internally packed, 3) low NiEDDA Π values and 
moderate/high O2 Π values suggest the residue is membrane exposed.  These numbers 
are not absolute because other factors such as oligomerization and multiple 
conformations can alter residue environments, but they are a guideline. 
For almost all residues tested, comparison of accessibility measurements for 
soluble and membrane associated LC-HCT showed a decrease in both NiEDDA and O2 
Π values (Table 2).  Normally a drop in Π values is associated with individual residues or 
with an individual paramagnetic species, either NiEDDA or O2.  A decrease across the 
board means that the membrane associated sample is somehow different in how it 
interacts with the environment.  A reason for this decrease could be due to crowding 
and/or oligomerization of the LC-HCT on the liposome surface.   
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Table 2. NiEDDA and O2 accessibility of MTSL-labeled LC-HCT single cysteine mutants. 
ΔΠ values are calculated from Π (PL, proteoliposome)-Π (sol, soluble).  % changes represent ΔΠ 
/ Π (sol) x 100 and are included for those residues that show a significant change in accessibility.  
Most residues decrease in both O2 and NiEDDA accessibilities when associated with liposomes.  
The few exceptions all have low accessibility to O2 in both the soluble and liposome-associated 
forms and are, therefore, not thought to lie within the membrane.          
 
 NiEDDA O2
Residue Π (PL) Π (sol) Δ Π % change Π (PL) Π (sol) Δ Π %change 
581 2.79 4.29 -1.5 -34.9 0.84 1.14 -0.30 -26.3 
605 1.04 1.78 -0.74 -41.5 0.37 0.68 -0.31 -45.6 
613 0.02 0.01 0.01  0.04 0.10 -0.06  
615 1.96 4.28 -2.32 -54.2 0.78 1.47 -0.69 -46.9 
631 1.04 2.52 -1.48 -58.7 0.59 0.73 -0.14 -19.1 
644 0.04 0.13 -0.09  0.26 0.10  0.16  
647 1.82 2.70 -0.88 -32.6 0.80 0.83 -0.03 -3.6 
654 0.43 0.90 -0.53 -58.9 0.30 0.51 -0.21 -41.2 
657 0.26 0.36 -0.10 -27.8 0.51 0.19 0.32 168 
662 1.34 3.17 -1.83 -57.7 0.53 0.83 -0.30 -36.1 
665 0.09 0.31 -0.22 -71 0.18 0.24 -0.06 -25.0 
666 0.14 0.63 -0.49 -77.8 0.17 0.34 -0.17 -50.0 
667 0.61 3.15 -2.54 -80.6 0.43 1.20 -0.77 -64.1 
669 3.05 4.02 -0.97 -24.1 1.02 1.33 -0.31 -23.3 
670 0.57 1.59 -1.02 -64.2 0.46 0.49 -0.03 -6.1 
671 1.32 3.14 -1.82 -58 0.70 0.96 -0.26 -27.1 
674 1.90 5.21 -3.31 -63.5 1.04 1.48 -0.44 -29.7 
679 3.37 4.12 -0.75 -18.2 1.01 1.21 -0.20 -16.7 
725 0.02 0.01 0.01  0.06 0.04 0.02  
750 1.55 2.21 -0.66 -29.8 0.67 0.95 -0.28 -29.5 
770 0.43 1.09 -0.66 -60.6 0.29 0.43 -0.14 -32.6 
774 0.81 1.66 -0.85 -51.2 0.47 0.81 -0.34 -42.0 
775 0.15 0.37 -0.22 -59.5 0.21 0.27 -0.06 -22.2 
817 1.50 1.95 -0.45 -23.1 0.73 1.16 -0.43 -37.1 
819 0.89 2.93 -2.04 -69.6 0.48 1.04 -0.56 -53.8 
823 1.35 2.46 -1.11 -45.1 0.78 1.37 -0.59 -43.1 
825 1.16 3.18 -2.02 -63.5 0.70 1.26 -0.56 -44.4 
827 2.34 4.21 -1.87 -44.4 1.04 1.24 -0.20 -16.1 
829 0.78 3.13 -2.35 -75.1 0.94 1.03 -0.09 -8.7 
833 1.14 2.81 -1.67 -59.4 0.82 1.23 -0.41 -33.3 
835 1.26 3.50 -2.24 -64.0 0.84 1.46 -0.62 -42.5 
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F657C-MTSL and N644C-MTSL show an increase in O2 and a decrease in NiEDDA.  
Normally this would suggest the residues lie within the membrane but with O2 values this  
low, it could also mean that the residue is repacking in a way where solvent is being 
crowded out within the protein. 
While the residues are not always consecutive, some trends in the data are worth 
noting. In the protected sequence identified in the protease protection assay, the NiEDDA 
accessibility seems to drop greater than the average decrease and the O2 accessibility 
does not seem to drop as much as other residues.  In particular L829C-MTSL shows a 
75% decrease in NiEDDA when associated with liposomes but a less than 10% decrease 
in O2.  Most residues tested in this region show NiEDDA Π values just above 1 but 
higher than average O2 values.  As described in Chapter 3, this region had the highest 
Fmem/Fsol values of all tested mutants suggesting that it moved into a more hydrophobic 
environment.  One would therefore expect the NiEDDA values to be minimal.  This 
apparent discrepancy can be attributed to differences in the NBD quenching and EPR 
accessibility measurements.  
 
Accessibility measurements versus NBD fluorescence.  
There are several possible explanations for why the accessibility measurements do 
not agree with the results obtained by protease protection and fluorescence quenching. 
The first is that any heterogeneity resulting from inefficient incorporation into the 
membrane will result in a mixed population of probe environments. The assays differ 
significantly in how a mixed population of states would be sampled; the NBD signal is 
likely to be dominated by residues shifting to a nonpolar environment while the EPR 
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signal is likely to be dominated by residues that are not inserted in the membrane. 
Secondly, if BoNT forms an oligomeric structure as it inserts, the interpretation of our 
accessibility values could become significantly more complicated. The possibility of 
oligomerization in this system is supported by the observation of spin-spin coupling in 
the I667C and K805C samples. Thirdly, it is possible that defined transmembrane 
structural elements do not exist, either in nature and/or in the conditions of our 
proteoliposomes. In electrophysiological measurements, the channel conductivity of 
BoNT requires a potential gradient, a difficult thing to implement and maintain in a 
liposome based system. Despite the success in using EPR to analyze the transmembrane 
states of diphtheria toxin, many biophysical studies point to the role of multiple insertion 
states, shallow and deep, as diphtheria toxin enters the membrane [105, 106]. With this in 
mind, the 825-837 region identified here by protease protection and NBD-fluorescence 
studies could represent a shallow insertion of the toxin.  
 
Docking of BoNT to membranes.  
We propose that the 825-837 region mediates an initial ‘docking’ interaction 
and/or shallow insertion into the membrane and that the presence of spin-spin coupling at 
residues I667 and K805 suggests that these residues represent part of an oligomerization 
interface (Figure 18).  To build a docking model for BoNT holotoxin, we also need to 
consider the position of the BoNT HCR. Multiple biochemical studies have highlighted 
the importance of ganglioside binding to the interaction of BoNT with the neuronal 
membrane [46] and a crystal structure of the GT1b ganglioside head group bound to 
BoNT/A HCR is known [107]. Using the crystal structure of BoNT/A holotoxin in its 
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soluble state, it is difficult to envision a membrane plane that would accommodate the 
ganglioside-binding site at W1265 and the 825-837 loop. Furthermore, the HCR position 
could occlude the formation of an oligomeric structure wherein I667C and K805C 
molecules would be capable of spin-spin coupling. In contrast, the position of the HCR in 
the crystal structure of BoNT/E is in a notably different position [28]. The ganglioside-
binding pocket in this structure would align easily into a membrane plane that 
accommodated the 825-837 loop. Furthermore, the structure can easily accommodate an 
oligomeric structure in which residues along the central helical axis can interact.   
 
Summary 
 
 We did extensive EPR analysis of sites within the protected region (805-837), the 
predicted transmembrane region (659-681), and throughout the HCT to assess the 
structural changes associated with BoNT insertion to form proteoliposomes.  The 
protected region showed no structural changes when going from the soluble to the 
liposome associated state.  The majority of the sites tested throughout HCT showed little 
to no change as well.  The 659-681 region was highly dynamic when transitioning 
between soluble and liposome associated forms.  We identified two residues, I667 and 
K805, that show spin-spin interaction at low pH in the presence of liposomes, possibly 
representing an oligomeric face.  These data and the crystal structures of BoNT/A and 
BoNT/E have allowed us to propose an initial model for how BoNT associates with 
liposomes at low pH.  
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Figure 18.  Model of membrane orientation based on BoNT/A and BoNT/E receptor 
binding domain (HCR) positions.  A) In this view, the HCR of BoNT/A (red) is positioned 
to the right of the HCT (light blue) with the ganglioside binding W1265 residue positioned in the 
‘back’ of the molecule.  The HCR in BoNT/E (orange) is positioned such that the W1265 and 
825-830 loop (green) could be located in a single plane. B) A top view of the HCT that highlights 
the position of the HCR from the BoNT/A (red) and BoNT/E (orange) structures.  The HCR 
position in the BoNT/E structure would accommodate an oligomerization model that includes the 
spin-spin coupling observed with I667C-MTSL and K805C-MTSL.  
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CHAPTER V 
 
 
CONCLUSIONS 
 
 
Summary 
 
 
Botulinum neurotoxin is the most potent toxin currently known.  The majority of 
the structural and experimental studies related to its mechanism of action have focused on 
its enzymatic and receptor-binding properties.  Pore formation has been studied using 
single channel and lipid bilayer techniques to establish that the pore is a cationic selective 
channel, the HCT is responsible for channel activity, and it is able to translocate the LC 
through the channel.  Unfortunately, like many pore-forming toxins, the details of how 
this process occurs are missing, mainly due to the inherent difficulty in studying 
membrane proteins.   
 Chapter II describes the characterization of a recombinant BoNT/A protein, LC-
HCT.  LC-HCT expresses as a soluble protein that can be ‘activated’ with trypsin to 
separate the domains which are tethered by a disulfide.  LC-HCT produces similar 
channel activity as holotoxin and can translocate the LC under low pH conditions.  
Unlike holotoxin, it has channel activity at neutral pH, although LC translocation does 
not occur.    It is able to be endocytosed and cleave endogenous SNAP25 when placed 
directly onto Neuro2A cells despite the absence of the HCR.   
 LC-HCT can be reconstituted to form proteoliposomes when added to anionic 
liposomes in low pH conditions.  This results in an irreversible binding to the liposomes 
that can be visualized by negative stain EM.   
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Chapter III describes the characterization of a C-terminal region protected from 
proteases when associated with liposomes.  The treatment of proteoliposomes with pepsin 
results in 2 distinct bands on an SDS-PAGE gel that are protected from pepsin.  Mass 
spectrometry analysis of these bands reveals common peptides that map to the C-terminal 
region of the HCT between residues K805-R837.  Labeling of this region with NBD, an 
environment sensitive dye, reveals that the loop R826-L837 shifts into a hydrophobic 
environment upon proteoliposome formation. This could mean it is inserting into the 
membrane or repacking into a more hydrophobic protein environment.  The region 
predicted to be a transmembrane helix, G659-V681, does not show this shift to a more 
hydrophobic environment. 
 Chapter IV describes the use of EPR to understand structural changes that occur 
during membrane association.  EPR lineshapes of residues in the R826-L837 loop show 
little change in lineshape when soluble and membrane bound protein are compared.  This 
revealed that the shift to a hydrophobic environment observed with NBD was not a result 
of local conformational changes.  The region composed of G659-V681 showed large 
lineshape changes upon membrane association, consistent with local structural changes in 
this region.  Lineshape analysis also revealed residues I667 and K805 show spin-spin 
interactions upon membrane association at pH 5 and pH 4.5, respectively.  Spin-spin 
interaction with K805 provides evidence for an oligomeric assembly of LC-HCT upon 
membrane association.  Spin-spin interaction of I667 disappears at pH 4.5 but its 
presence at pH 5.0 suggests an intermediate oligomeric form.          
 Accessibility measurements were used to probe the environment of the spin label 
to determine if the residues being tested lie within the membrane.  Mutants in LC-HCT 
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generally showed a decrease in accessibility to both NiEDDA and O2 when associated 
with liposomes, consistent with the crowding of solvent.  Only N644 and F657 showed 
an increase in O2 accessibility and a decrease in NiEDDA accessibility, although the 
magnitudes of the changes were very low.  The general decrease in accessibility to 
NiEDDA and O2 suggests that LC-HCT in proteoliposomes may be a heterogeneous 
sample thus making accessibility measurements very difficult to interpret.   
 
Future Directions 
 
Further Characterization of the Protected Peptides 
 The protected peptides described in Chapter III have provided a framework for 
understanding how BoNT interacts with membranes.  The NBD data suggest the most 
abundant protected peptide, 805-837, associated the peptide lies within the bilayer.  We 
can determine if the peptide lies within the membrane by using spin-labeled lipids as 
short distance quenchers of the NBD fluorescence increase.  The incorporation of doxyl 
containing lipids into the liposomes should allow us to identify NBD-labeled residues 
that lie within the membrane.  Incorporating the doxyl-group at different positions within 
the hydrocarbon chain should provide depth information.  This method has been utilized 
when determining the membrane spanning domain for perfringolysin O [76]. 
   Another interesting aspect of the 805-837 peptide is the number of charged 
amino acids.  Positive amino acids within transmembrane spanning regions can define the 
orientation for insertion by making interactions with the lipid headgroups.  In channels 
such as the potassium channel, they can serve as voltage gates.  It would be interesting to 
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understand what roll, if any, these positive amino acids play in transmembrane insertion 
and voltage gating [95, 96].  The NBD data show that residue R826, which lies in the 
loop region of the protected peptide, has a remarkable increase in fluorescence upon 
association with the liposomes.  Mutants of arginines and lysines within 805-837 could 
be tested by single channel patch clamp to see how they deviate from the wildtype 
channels in channel formation, gating, and channel conductance.   
 There were 3 other protected peptides that were identified by mass spectrometry 
from the 5 kDa band (Figure 12).  One peptide 319-KYLLSEDTSGKF is within the LC 
and 700-KRNEKWDEVYKY and 719- KVNTQIDLIRK are in the HCT.  It would be 
interesting to understand why both the 319 and 700 region peptides are protected and 
what roll they play in membrane association or translocation (Figure 19).  The 700 and 
719 peptides are a continuous region that lies adjacent to and makes hydrophobic 
contacts with the 805-826 region.  These hydrophobic contacts are capped on the top by 
the 659 region that shows movement upon membrane association.  This region has 
sequence similarity to a region in diphtheria toxin that is known to interact with the 
catalytic domain during translocation [108].  NBD studies through this region would be 
useful in determining if it is making contacts with the membrane.  Although the 319 
peptide is not involved in pore formation it seems reasonable that some of the LC would 
contact the membrane during the membrane binding and translocation.  Any details on 
the LC from NBD measurements would help in building a more clear association model.     
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 Figure 19. Locations of 3 major peptides from 5 kDa band.  The 805 peptide (green) 
was the focus of Chapters III and IV.  The 700 (dark blue) and 319 (red) peptides also 
showed enrichment in the 5 kDa protected band.  Further analysis of these peptides by 
NBD fluorescence and EPR might give insight into how LC-HCT interacts with 
membranes.   
 
 
 
 
 67
Oligomerization of BoNT 
 Oligomerization is an important mechanistic aspect of pore-forming toxins such 
as anthrax toxin [109, 110].  Crystallization and electron microscopy have been the main 
techniques in determining the oligomerization state of pore forming toxins.  
Unfortunately BoNT has all but eluded the determination if it has an oligomeric pore 
state.  One electron crystallography study has suggested that BoNT is capable of forming 
tetramers but no further work has been able to provide any evidence to support or refute 
this[111]. 
 The spin-spin interactions of residues 667 and 805 presented in Chapter IV give a 
second glimpse into the oligomeric state of BoNT upon membrane association.  LC-HCT 
is purified as a monomer, but upon liposome association, the spin-spin coupling suggests 
that at least 2 monomers are coming into close proximity.  The spin interactions can be 
titrated by mixing labeled and unlabeled LC-HCT.  Titration would result in loss of spin 
interaction until full signal is returned, and should allow one to assess the oligomeric 
state of the protein.  A potential problem with this method is that spin-spin interaction 
requires high labeling efficiency usually greater than 95%.  Lower labeling efficiency 
may remove signs of the spin-spin interaction or distort the oligomerization estimate 
since the oligomer would be a mixture of labeled and unlabeled protein prior to titration. 
     Gel filtration or Blue Native Page would be two similar methods at determining 
the oligomeric state.  Both gel filtration and Blue Native can be used to determine the 
size of complexes.  Currently the issue that has hampered these efforts from going 
forward is solublizing LC-HCT that has been associated with liposomes.  The liposome 
itself is very large, variable in size, and is effectively treated as a precipitate once LC-
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HCT has been associated.  Prior to employing these methods, we will need to find a way 
of solublizing the BoNT from the liposome in a way that does not disturb the complex.  
This would require detergent screening in order to find a detergent that would support the 
same structure found in liposomes.  It will also be important to see if we can repeat the 
line-shape and NBD measurements going directly into detergent micelles.  The 
measurements we have from liposomes would provide a baseline for what line-shape or 
fluorescence changes we should see and would allow us to decide if the detergent is 
supporting similar structural changes in LC-HCT.   
  
Crystallization of LC-HCT in the Membrane Associated State 
X-Ray crystallography is a powerful method that would allow us to determine the 
oligomeric state of LC-HCT when associated with membranes but also provide details of 
the pore itself.  Crystallization will require proper detergent that supports a homogeneous 
and stable pore structure.  2D crystallization is an alternative that could be done on a lipid 
monolayer.  It would require LC-HCT to insert directly into the lipid layer without a pH 
gradient.  Empirical assessment of conditions to generate 3D or 2D crystals will represent 
a priority for future studies aimed at generating an atomic model of pore structure. 
 
Concluding Remarks 
 The future direction proposed here will build upon the method development that 
has occurred over the course of this study.  The continued use of fluorescence and EPR 
assays, will not only help to refine our technique of reconstitution, but allow us to expand 
our knowledge of how BoNT interacts with membranes. 
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APPENDIX 
 
Table 3. LC-HCT mutants defective in expression, stability, or labeling. 
 
Mutant Expression Stability MTSL Label 
W42C No -- -- 
W117C Poor -- No 
T583C Yes -- Poor 
F584C Yes -- Poor 
F585C Yes -- Poor 
S587C Yes Precipitates upon addition of MTSL No 
D588C Yes 50% Dimer Formation Poor 
V606C Yes -- Poor 
T617C Yes -- Poor 
V661C Yes Nearby nicking with trypsin Yes 
I662C Yes Nearby nicking with trypsin Yes 
E665C Yes Some autocleavage of LC Yes 
F666C Yes Some autocleavage of LC Yes 
P668C Yes -- No 
W705C Poor -- Very Poor 
Y709C Yes -- Very Poor 
W716C Very Poor -- No 
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